Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.
Pulmonary hypertension (PH) is an increasingly recognized complication of premature birth and bronchopulmonary dysplasia (BPD), and is associated with increased morbidity and mortality. Extreme phenotypic variability exists among preterm infants of similar gestational ages, making it difficult to predict which infants are at increased risk for developing PH. Intrauterine growth retardation or drug exposures, postnatal therapy with prolonged positive pressure ventilation, cardiovascular shunts, poor postnatal lung and somatic growth, and genetic or epigenetic factors may all contribute to the development of PH in preterm infants with BPD. In addition to the variability of severity of PH, there is also qualitative variability seen in PH, such as the variable responses to vasoactive medications. To reduce the morbidity and mortality associated with PH, a multi-pronged approach is needed. First, improved screening for and increased recognition of PH may allow for earlier treatment and better clinical outcomes. Second, identification of both prenatal and postnatal risk factors for the development of PH may allow targeting of therapy and resources for those at highest risk. Third, understanding the pathophysiology of the preterm pulmonary vascular bed may help improve outcomes through recognizing pathways that are dysregulated in PH, identifying novel biomarkers, and testing novel treatments. Finally, the recognition of conditions and exposures that may exacerbate or lead to recurrent PH is needed to help with developing treatment guidelines and preventative strategies that can be used to reduce the burden of disease.
Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2533, USA.
Joseph M
JM
Collaco
Lewis H
LH
Romer
Bridget D
BD
Stuart
John D
JD
Coulson
Allen D
AD
Everett
Edward E
EE
Lawson
Joel I
JI
Brenner
Anna T
AT
Brown
Melanie K
MK
Nies
Priya
P
Sekar
Lawrence M
LM
Nogee
Sharon A
SA
McGrath-Morrow
D000758:Anesthesia / Q000009:adverse effects; D015415:Biomarkers / Q000032:analysis; D001997:Bronchopulmonary Dysplasia / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D006328:Cardiac Catheterization / Q000379:methods; D002648:Child; D002675:Child, Preschool; D004452:Echocardiography / Q000379:methods; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D015995:Prevalence; D012307:Risk Factors; D012720:Severity of Illness Index
D015415:Biomarkers